Published in J Natl Cancer Inst on August 29, 2013
Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab (2014) 2.17
Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst (2014) 1.68
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Prevalence of hypercalcemia among cancer patients in the United States. Cancer Med (2016) 0.89
Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy. BMJ Case Rep (2014) 0.83
Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy. Endocrinol Diabetes Metab Case Rep (2015) 0.75
Response. J Natl Cancer Inst (2014) 0.75
Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery. Skeletal Radiol (2017) 0.75
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Clinical practice. Hypercalcemia associated with cancer. N Engl J Med (2005) 3.88
Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci U S A (1987) 3.06
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol (2001) 2.72
Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest (1987) 2.41
Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem (1987) 2.30
Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. Annu Rev Med (1994) 1.49
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res (2012) 1.26
High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med (2002) 11.28
Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med (2012) 3.86
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg (2012) 2.35
Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab (2008) 2.30
Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol (2008) 2.23
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol (2008) 2.23
The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab (2009) 2.22
Assessment of the cost of fine-needle aspiration cytology as a diagnostic tool in patients with thyroid nodules. Am J Clin Pathol (2008) 2.18
Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab (2014) 2.17
Management of retropharyngeal node metastases from thyroid carcinoma. World J Surg (2015) 1.98
Multisystem study of 20 older adults with Williams syndrome. Am J Med Genet A (2004) 1.61
Characterization and fate of telomerase-expressing epithelia during kidney repair. J Am Soc Nephrol (2011) 1.52
Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid (2005) 1.32
Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer (2013) 1.31
Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab (2006) 1.30
Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med (2009) 1.27
Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol (2013) 1.25
131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med (2008) 1.17
Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab (2003) 1.17
Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol (2008) 1.17
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab (2007) 1.16
Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.15
Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med (2006) 1.14
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab (2012) 1.11
The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone. Endocrinology (2004) 1.09
Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging (2007) 1.08
Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab (2006) 1.08
High rate of multifocality and occult lymph node metastases in papillary thyroid carcinoma arising in thyroglossal duct cysts. Ann Surg Oncol (2009) 1.08
Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab (2012) 1.06
Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood (2009) 1.05
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab (2013) 1.05
Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone (2005) 1.03
Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol (2010) 1.02
Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab (2011) 1.01
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer (2009) 1.01
Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone (2007) 1.01
Multiple melanocortin receptors are expressed in bone cells. Bone (2005) 1.00
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res (2011) 1.00
Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab (2010) 1.00
Influence of prophylactic neck dissection on rate of retreatment for papillary thyroid carcinoma. World J Surg (2013) 0.98
Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol (2011) 0.98
Activated c-Fms recruits Vav and Rac during CSF-1-induced cytoskeletal remodeling and spreading in osteoclasts. Bone (2006) 0.97
Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res (2008) 0.96
Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab (2002) 0.96
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer (2009) 0.96
Expression and synthesis of bone morphogenetic proteins by osteoclasts: a possible path to anabolic bone remodeling. J Histochem Cytochem (2008) 0.95
Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology (2010) 0.95
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol (2011) 0.95
L-type amino acids stimulate gastric acid secretion by activation of the calcium-sensing receptor in parietal cells. Am J Physiol Gastrointest Liver Physiol (2005) 0.93
18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging (2010) 0.91
Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid (2012) 0.91
Food and oral antineoplastics: more than meets the eye. Clin Cancer Res (2010) 0.91
The cell surface form of colony-stimulating factor-1 is biologically active in bone in vivo. Endocrinology (2003) 0.90
An aerobic weight-loaded pilot exercise intervention for breast cancer survivors: bone remodeling and body composition outcomes. Biol Res Nurs (2008) 0.90
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer (2014) 0.90
Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence. Ann Surg Oncol (2009) 0.89
Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab (2011) 0.89
Thyroid metastases from colorectal cancer: the Institut Gustave Roussy experience. Eur J Cancer (2006) 0.89
Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy. Eur J Radiol (2007) 0.89
High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol (2011) 0.88
Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. Cancer (2007) 0.88
Clinical review: Current concepts in the management of unilateral recurrent laryngeal nerve paralysis after thyroid surgery. J Clin Endocrinol Metab (2005) 0.87
Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab (2011) 0.86
Gemcitabine-Induced Pseudocellulitis in a Patient With Recurrent Lymphedema: A Case Report and Review of the Current Literature. Am J Ther (2016) 0.86
Osteoclasts lacking Rac2 have defective chemotaxis and resorptive activity. Calcif Tissue Int (2010) 0.86
Primary adrenal angiosarcoma and functioning adrenocortical adenoma: an exceptional combined tumor. Eur J Endocrinol (2011) 0.86
Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers (2011) 0.86
Breast cancer-associated gene 3 (BCA3) is a novel Rac1-interacting protein. J Bone Miner Res (2007) 0.85
Treatment and follow-up of low-risk patients with thyroid cancer. Nat Rev Endocrinol (2011) 0.85
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol (2014) 0.85
A patient with hypophosphatemia, a femoral fracture, and recurrent kidney stones: report of a novel mutation in SLC34A3. Endocr Pract (2008) 0.84
One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2013) 0.84
F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res (2007) 0.84
FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer (2011) 0.84
Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging (2002) 0.84
LIM kinase 1 deficient mice have reduced bone mass. Bone (2012) 0.83
Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J Clin Endocrinol Metab (2013) 0.83
Continuous flow peritoneal dialysis: principles and applications. Semin Dial (2003) 0.83
Torus palatinus: a new anatomical correlation with bone density in postmenopausal women. J Clin Endocrinol Metab (2003) 0.82
The anabolic response to parathyroid hormone is augmented in Rac2 knockout mice. Endocrinology (2008) 0.82
Role of prophylactic thyroidectomy in RET 790 familial medullary thyroid carcinoma. Head Neck (2011) 0.81
Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. Cardiovasc Intervent Radiol (2014) 0.81
In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender. Neuro Endocrinol Lett (2007) 0.80
Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer (2013) 0.80
Kinase inhibitors for advanced medullary thyroid carcinoma. Clinics (Sao Paulo) (2012) 0.80
Resection margins and prognosis in locally invasive thyroid cancer. Head Neck (2013) 0.80
Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol (Oxf) (2005) 0.80
Osteomalacia due to adult Fanconi syndrome in multiple myeloma. Leuk Lymphoma (2011) 0.80
Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol (2010) 0.79
The transcription factor T-box 3 regulates colony-stimulating factor 1-dependent Jun dimerization protein 2 expression and plays an important role in osteoclastogenesis. J Biol Chem (2014) 0.79
The cell-surface isoform of colony stimulating factor 1 (CSF1) restores but does not completely normalize fecundity in CSF1-deficient mice. Biol Reprod (2005) 0.79
Targeted overexpression of the two colony-stimulating factor-1 isoforms in osteoblasts differentially affects bone loss in ovariectomized mice. Am J Physiol Endocrinol Metab (2009) 0.78
Thyroid cancer patients treated with 131I: radiation dose to relatives after discharge from the hospital. Thyroid (2011) 0.78